This is a randomised, parallel, masked, active-controlled study that will evaluate the efficacy and safety of a low dose and a high dose of PA5108 Ocular Implant with single redosing during the study, in adults with open-angle glaucoma or ocular hypertension.
The study will also collect information on the implant administration procedure and overall experience from study participants.
The study plans to recruit approximately 75 participants.
Eligible participants will be randomly selected to receive one of the following treatments:
* PA5108 Ocular Implant - low dose in the study eye, and Latanoprost 0.005% eye drops in the other eye
* PA5108 Ocular Implant - high dose in the study eye, and Latanoprost 0.005% eye drops in the other eye
* Latanoprost 0.005% eye drops in both eyes (control treatment group) If allocated to receive either of the ocular implants, a second implant of the same dose will be administered at 26 weeks and participants will be followed for safety and intraocular pressure control until week 58 or until the implant is no longer visible in the study eye.
